These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 11416282)

  • 1. Studies of Left Ventricular Dysfunction (SOLVD).
    Nauman D; Greenberg B
    Am J Geriatr Cardiol; 1993 Jan; 2(1):28-36. PubMed ID: 11416282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    Yusuf S
    Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB; Yusuf S; Naylor CD
    Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
    Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
    Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
    Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
    Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
    Buch P; Rasmussen S; Abildstrom SZ; Køber L; Carlsen J; Torp-Pedersen C;
    Eur Heart J; 2005 Jan; 26(2):145-52. PubMed ID: 15618070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure.
    Tarantini L; Faggiano P; Senni M; Lucci D; Bertoli D; Porcu M; Opasich C; Tavazzi L; Maggioni AP
    Ital Heart J; 2002 Nov; 3(11):656-64. PubMed ID: 12506524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
    J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.